Retatrutide对肥胖伴或不伴2型糖尿病患者的脂质与代谢物谱影响
两项随机安慰剂对照2期试验的事后探索性分析,对肥胖(n=282)和2型糖尿病(n=213)受试者进行代谢组学和脂质组学检测。Retatrutide高剂量与脂肪酸氧化相关代谢物簇及胰岛素抵抗相关代谢物改变相关,这些改变方向与代谢健康改善和心血管风险降低一致。
要点
- Retatrutide改变3-羟基丁酸、乙酰肉碱等脂肪酸氧化相关代谢物
- 上述代谢物介导了无T2D者23.2%的体重下降反应,T2D者减弱至12.7%
- Retatrutide还改变支链氨基酸、2-氨基己二酸等胰岛素抵抗相关代谢物
核心结论
- Retatrutide与两个代谢簇的改变相关:脂肪酸氧化和胰岛素抵抗,方向与代谢健康改善和心血管风险降低一致。
研究设计与样本
- 两项随机、安慰剂对照2期试验的事后探索性分析,对空腹样本进行代谢组学和脂质组学检测。
- 肥胖试验282例,治疗36周;T2D试验213例,治疗48周。
- 肥胖试验干预为retatrutide 1、4、8、12 mg或安慰剂;T2D试验为retatrutide 0.5、4、8、12 mg或安慰剂或度拉糖肽1.5 mg。
主要发现
- 在两个人群的主要终点和研究终点,较高剂量retatrutide与包含3-羟基丁酸、乙酰肉碱、游离肉碱和脂肪酸来源长链酰基肉碱的代谢物簇改变相关。
- 中介分析提示这些生物标志物改变介导了无T2D参与者23.2%的体重下降反应,在T2D参与者中减弱至12.7%。
- Retatrutide还与胰岛素抵抗相关代谢物改变相关,包括支链氨基酸及其分解产物、2-氨基己二酸、2-羟基丁酸、尿酸和富含短链及饱和酰基侧链的甘油三酯。
- 这些改变在两个研究人群中均可见,并在研究终点持续存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c and improved the lipid profiles of participants living with obesity, with and without T2D. OBJECTIVE: Assess plasma metabolome and lipidome changes associated with retatrutide treatment. METHODS: Metabolomics and lipidomics were performed in fasting samples from 2 randomized, placebo-controlled phase 2 trials as a post hoc exploratory analysis. Participants living with obesity with and without T2D were treated for 36 and 48 weeks, respectively. There were 282 and 213 participants in the obesity and T2D trials, respectively and the intervention(s) received were: Obesity trial: retatrutide (1, 4, 8, and 12 mg) or placebo; T2D trial: retatrutide (0.5, 4, 8, and 12 mg) or placebo or dulaglutide (1.5 mg). The main outcome measure(s) were changes in metabolite and lipid levels with retatrutide treatment against baseline levels and placebo using multiplicity correction. RESULTS: At both primary and study endpoints for both populations, higher doses of retatrutide were associated with changes in a cluster of metabolites comprising 3-hydroxybutyrate, acetylcarnitine, free carnitine, and fatty acid-derived long-chain acylcarnitines. Mediation analyses suggested that changes in these biomarkers mediated 23.2% of the weight reduction response in participants without T2D and that this mediation was blunted to 12.7% in participants with T2D. Retatrutide treatment was also associated with changes in metabolites associated with insulin resistance, including branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains. These changes were found in both study populations and sustained across study endpoints. CONCLUSION: Retatrutide was associated with changes in 2 metabolic clusters related to fatty acid oxidation and insulin resistance in a direction associated with improved metabolic health and reduced cardiovascular risk.
引用
- Pearson MJ, Willency JA, Lin Y, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195. doi:10.1210/clinem/dgag201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。